Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mecasermin rinfabate - Oak Hill Bio/ Takeda

Next Previous
X
Search
Drug Profile

Mecasermin rinfabate - Oak Hill Bio/ Takeda

Alternative Names: HGT-ROP-001; IGF-I/IGFBP-3; Insulin-like growth factor-I/insulin-like growth factor binding protein-3; IPLEX; Mecasermin rinfabate; OHB-607; Premiplex; rhIGF-I/rhIGFBP-3; SHP607; SomatoKine; Somatomedin-C/Somatomedin-1-binding-protein-3; TAK 607

Latest Information Update: 24 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Insmed
  • Developer Insmed; Oak Hill Bio; Takeda
  • Class Antihyperglycaemics; Eye disorder therapies; Growth factors; Osteoporosis therapies; Recombinant proteins
  • Mechanism of Action Insulin like growth factor binding protein 3 stimulants; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Insulin resistance; Muscular dystrophies; Growth disorders; Retinopathy of prematurity
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchopulmonary dysplasia
  • Market Withdrawal Growth disorders
  • Suspended Muscular dystrophies
  • No development reported Amyotrophic lateral sclerosis; Retinopathy of prematurity
  • Discontinued Burns; Fracture; Insulin resistance; Lipodystrophy; Postmenopausal osteoporosis; Short stature; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 17 May 2024 Oak Hill Bio re-initiates phase-IIb trial for Bronchopulmonary dysplasia (In neonates, Prevention) in USA, United Kingdom, Sweden, Spain, Portugal, Netherlands, Japan, Italy, Ireland, Germany, France, Finland, Canada (IV) (NCT03253263)
  • 10 Jan 2024 Chiesi Group entered into research and development agreement with Oak Hill for the development of OHB-607
  • 09 Jan 2024 Chiesi Group and Oak Hillplans plans to re-initiate phase IIb trial for Bronchopulmonary dysplasia in the United States, Europe, and Japan in 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top